Personal-Use Self-monitoring Blood Glucose Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Personal-Use Self-monitoring Blood Glucose Devices Market Analysis

The personal-use self-monitoring blood glucose devices market size reached USD 4.40 billion in 2025 and is forecast to touch USD 6.10 billion by 2030, advancing at a 6.75% CAGR during the period. The expansion reflects the compound effect of rising diabetes prevalence, population aging, and steady reimbursement gains for connected meters. Continuous sensor innovation, smartphone integration, and over-the-counter (OTC) clearances broaden the addressable base beyond insulin-dependent patients, while real-time analytics improve therapeutic decision-making. Growth also benefits from expanding wellness adoption among non-diabetic consumers and sustained venture funding that accelerates miniaturized, low-power designs. Competitive intensity remains moderate but is sharpening as scale players link glucose data with automated insulin delivery, digital coaching, and generative AI platforms.

Global Personal-Use Self-monitoring Blood Glucose Devices Market Trends and Insights

Rising Diabetes Prevalence & Ageing Population

Global diabetes prevalence could exceed 783.2 million by 2045, creating sustained demand for easy-to-use monitors. The burden is pronounced in Asia-Pacific, where China already records a 13.67% prevalence and faces a projected 29.1% rate by 2050. Older adults need simplified interfaces, larger displays, and dependable connectivity, prompting manufacturers to refine ergonomy and voice-guided prompts. Combined demographic and disease pressures ensure that the personal-use self-monitoring blood glucose devices market continues expanding even in reimbursement-constrained settings. The sheer volume of potential users underpins long-run volume growth that can absorb price erosion.

Smartphone-Linked Smart Meters Gain Reimbursement Traction

Medicare aligned coverage rules with ADA guidance in 2023, waiving finger-stick confirmation and adding basal-only Type 2 patients, thereby subsidizing 80% of approved CGM system costs. Commercial payers quickly followed, citing documented A1c reductions and reduced hypoglycemia events. In Europe, Norway and Belgium introduced national funding for sensor-based monitors, while additional markets evaluate similar moves. Reimbursement cuts out-of-pocket cost, fostering mainstream adoption and enabling vendors to bundle smartphones, apps, and cloud portals. As insurers link sensor data with population-health analytics, reimbursement remains a decisive pull factor for the personal-use self-monitoring blood glucose devices market.

High Lifetime Cost of Consumables (Strips / Sensors)

Annual CGM ownership ranges between USD 1,200 and USD 3,600, while 100-count strip boxes retail from USD 35 to USD 170, squeezing uninsured and low-income users. Even Dexcom’s value-priced Stelo still averages USD 100 per month. Surveys across six developing countries confirm affordability gaps that dampen sustained monitoring adherence. Manufacturers respond with longer-life sensors and bundle discounts, yet volume-driven cost declines remain gradual. Without broader subsidies, consumable burden continues to temper uptake in price-sensitive segments of the personal-use self-monitoring blood glucose devices market.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Continuous & Flash GM Into Type-2 Pre-Diabetes
2. OTC Approval of Non-Invasive Optical Meters
3. Accuracy Gaps vs. Lab Reference in Tropical Climates

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Test strips captured 65.25% of the personal-use self-monitoring blood glucose devices market in 2024, preserving a high-margin replenishment stream that underwrites manufacturer cash flows. Devices, however, are registering the quickest 9.25% CAGR as users pivot to integrated, sensor-rich platforms that lower per-reading cost over time. Longer wear sensors such as Dexcom G7 15-Day demonstrate how hardware upgrades decrease monthly spend and improve convenience. Accessories—from lancet drums to smartphone cradles—command modest but rising revenue as connectivity and comfort influence brand choice.

Glucometer innovation now targets single-platform ecosystems that pair proprietary sensors with AI-driven apps. Abbott’s FreeStyle Libre 2 Plus, the first U.S. CGM to link directly with automated insulin delivery, illustrates the hardware-software convergence reshaping the personal-use self-monitoring blood glucose devices market. Vendors also trial reusable optical readers designed to leverage strip-free photonics, potentially compressing consumable demand. While strips remain dominant, incremental sensor advances steadily shift revenue weight toward durable equipment and cloud subscriptions.

Self-monitoring blood glucose still holds 35.53% share, anchored by affordability and clinician familiarity. Nevertheless, continuous sensors are outpacing at 12.35% CAGR because real-time trend data reduce hypoglycemia risk and support dose titration. Randomized studies in primary care show CGM users achieving HbA1c drops of 1.3 percentage points versus 0.8 points for finger-stick cohorts. Non-invasive optical prototypes demonstrate accelerating accuracy gains, aided by machine-learning spectroscopic algorithms.

Technology suppliers bundle sensors with telehealth dashboards, broadening clinical oversight and unlocking insurer value-based payments. Medtronic’s Simplera disposable CGM, half the size of its predecessor, shows how form-factor reductions drive comfort and adoption. As reimbursement spreads and component costs fall, CGM looks set to erode SMBG leadership across the personal-use self-monitoring blood glucose devices market.

The Personal-Use Self Monitoring Blood Glucose Devices Market Report is Segmented by Component (Glucometer Devices, Test Strips, and More), Technology (SMBG (Capillary), Continuous Glucose Monitoring (Personal), and More), Connectivity (Wired / USB, NFC, and More), End-User (Home-Care / Personal and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America led the personal-use self-monitoring blood glucose devices market with 42.82% revenue share in 2024 on the back of payer funding, early tech uptake, and robust distribution networks. Medicare’s expanded coverage and successive private-payer updates have widened eligibility for continuous sensors, spurring double-digit unit growth. The U.S. FDA’s friendly stance toward OTC clearances further enlarges the consumer funnel and shortens go-to-market cycles. Canada mirrors these trends, advancing national reimbursement pilots for flash sensors.

Asia-Pacific is projected to log a 12.62% CAGR through 2030 as high prevalence converges with rising middle-class disposable income. China’s digital health programs demonstrate that integrated platforms can trim fasting glucose by 1.68% and HbA1c by 0.45 points among engaged users. India’s uptake of point-of-care HbA1c screening, with an ICUR of just USD 185.10/QALY in rural settings, underscores economic viability. Government initiatives to localize sensor assembly are also likely to shrink end-user prices, fuelling further expansion of the personal-use self-monitoring blood glucose devices market.

Europe maintains stable mid-single-digit growth, underpinned by national funding steps such as Norway’s 2023 decision to reimburse sensor-based monitors. The EU’s Medical Device Regulation harmonizes safety benchmarks, favoring firms with rigorous quality systems. Meanwhile, Latin America and Middle East-Africa show rising incidence but adoption lags due to cost and limited payer coverage. Nevertheless, philanthropic procurement and telehealth pilots in Gulf Cooperation Council states foreshadow incremental upside.

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Roche
3. LifeScan Inc
4. Arkray
5. Ascensia
6. AgaMatrix
7. Bionime
8. Acon Laboratories
9. Medisana
10. Rossmax
11. Dexcom
12. Medtronic
13. Insulet
14. Senseonics
15. OMRON
16. i-SENS
17. Ypsomed
18. Terumo
19. Nova Biomedical
20. ForaCare
21. DarioHealth
22. Trividia Health
23. Beckton Dickinson
24. iHealth Labs

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support